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Abstract
Percutaneous coronary intervention for the treatment of coronary artery disease
is most commonly performed in the UK through the radial artery, as this is safer
than the femoral approach. However, despite improvements in technology and
techniques, complications can occur. The most common complication, arterial
spasm, can cause intense pain and, in some cases, procedural failure. The
incidence of spasm is dependent on several variables, including operator
experience, artery size, and equipment used. An anti-spasmolytic cocktail can be
applied to reduce spasm, which usually includes an exogenous nitric oxide (NO)
donor (glyceryl trinitrate). NO is an endogenous local vasodilator and therefore is
a potential target for anti-spasm intervention. However, systemic administration
can result in unwanted side-effects, such as hypotension. A method that adopts
local delivery of NO might be advantageous. This review article describes the
mechanisms involved in radial artery spasm, discusses the advantages and
disadvantages of current strategies to reduce spasm, and highlight the potential
of NO-loaded nanoporous materials for use in this setting.
Key words: Radial artery; Cannulation; Spasm; Nitric oxide; Vasodilation; Nanoporous
material
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Core tip: Radial access during interventional cardiology procedures is much safer than
femoral access although complications can still arise. However, the radial artery is more
prone to spasm which can cause pain for the patient and lead to procedural failure.
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Current strategies to avoid spasm include administration of an anti- spasmolytic cocktail.
Several disadvantages towards the use of this “cocktail” leaves a gap in the industry for a
new product to dilate the artery without any systemic effects.
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INTRODUCTION
Coronary artery disease is a major cause of mortality and morbidity worldwide[1,2].
The underlying disease process, atherosclerosis, results in the accumulation of lipid
plaque in the arterial intima. Atherosclerosis is triggered by endothelial dysfunction
and can lead to reduced coronary blood flow, resulting in angina or myocardial
infarction with a reduction in patient survival and quality of life[3-5]. Treatments for
occlusive coronary artery disease are divided into three major categories: Medical
therapy  alone,  concomitant  coronary  artery  bypass  grafting,  or  concomitant
percutaneous coronary intervention (PCI). PCI was introduced in 1977 by Grüntzig et
al[7] and is now the most common procedure used to treat diseased coronary arteries[6],
improving symptoms and reducing mortality in certain patients[6,7].
There have been considerable technological advances in PCI since its inception,
with  the  introduction  of  improved  delivery  equipment,  intracoronary  stents,
improvement in stent design and introduction of anti-proliferation stent coatings,
resulting  in  improved  procedural  success  and  patient  outcomes.  In  the  United
Kingdom, PCI is most commonly performed through the radial artery (RA) because
this is considered to be safer than the femoral approach. However,  despite these
developments, complications associated with PCI persist.  These include vascular
access  site  complications,  coronary  artery  complications  and  procedure-related
complications,  such  as  embolism  or  renal  dysfunction  caused  by  radio-opaque
contrast[8]. The most common complications are related to the vascular access site.
This review article describes the mechanisms that are involved in RA spasm and
discusses strategies to reduce spasm and improve outcomes, with a particular focus
on the potential for novel nitric oxide (NO) materials in this setting.
PCI ACCESS SITES
Vascular access can be achieved via the femoral artery or, more recently, the RA[9-11].
Although femoral artery access is still used, it has several disadvantages compared to
the RA approach, including longer bed rest, difficult access through the tortuous
aorta,  the  need for  puncture  site  compression after  the  procedure,  and vascular
complications of arteriovenous fistula and haematoma[9]. Furthermore, the femoral
artery is an ‘end artery’ with limited alternative vascular pathways to contribute to
lower limb perfusion. As a result, vascular complications can lead to limb loss[12]. The
RA  approach  was  introduced  in  1989  by  Campeau  et  al[13]  and  has  been  used
increasingly for interventional and diagnostic cardiology over the last thirty years.
Studies have shown that, compared with the femoral approach, the radial method
has reduced bleeding risk, earlier hospital discharge, lower cost, reduced haematoma
formation, lower mortality and morbidity, and is preferred by most patients[14-18].
However,  it  carries  technical  challenges,  not  least  on  account  of  the  small  RA
diameter, which hinders instrument insertion and increases artery-instrument contact,
heightening the risk of disruption to the endothelial surface, which increases the risk
of spasm.
As the RA approach is becoming more commonly used, there is a greater need to
reduce the risk of complications.
THE RADIAL ARTERY: ANATOMICAL AND PHYSIOLOGICAL
CONSIDERATIONS
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Anatomy
The RA runs along the lateral part of the front of the forearm beside the superficial
branch of the radial nerve[19,20]. Variation in the anatomy of the RA is less frequent in
the distal forearm, where arterial cannulation is commonly performed[18,19,21]. Arterial
blood flow is provided to the hand through a dense anastomotic network of four
arches created from the radial and ulnar arteries. The complexity of the anatomy of
the RA ensures substantial  collateral blood flow is instrumental in ensuring that
cannulation (and occlusion) is generally well-tolerated.
The RA has a thick tunica media composed of mainly smooth muscle cells with a
high density of α1 adrenoceptors (Figure 1). High density sympathetic innervation,
coupled with a thick, muscular wall makes the RA highly susceptible to spasm; the
predominance of  α-adrenoceptors  leads to rapid vasoconstriction in response to
stress-induced local  release of  the catecholamine,  noradrenaline[22,23].  Anomalous
radial artery anatomy and small artery diameter are major predisposing factors which
can determine the development of spasm[24]. During cannulation, spasm can cause the
vessel to “clamp” onto the guide catheter, which can result in pain for the patient and
procedural difficulty for the operator, limiting successful completion. Spasm then
exacerbates friction between the arterial wall and the sheath, which acts to intensify
the spasm and induce a positive feedback loop (Figure 1). This continuous cycle of
events can lead ultimately to intimal tear and thrombus formation in the artery[25,26].
Once catheters are inserted through a sheath, spasm can occur at other sites at any
level from the RA to the subclavian artery[26].
NO - a powerful endogenous local vasodilator and anti-platelet agent
NO  is  an  endogenous  biological  signalling  molecule  that  mediates  a  variety  of
biological  functions  in  the  cardiovascular,  immune  and  nervous  systems[5].  NO
mediates vasodilatation, cell proliferation and inhibition of platelet adhesion[27-29].
The  importance  of  NO in  biological  processes  was  first  realised  when  it  was
identified as an endothelium-derived relaxing factor that is released by the vascular
endothelium and mediates vasodilation. It has long been known that endogenous NO
is reduced or absent in coronary arteries affected by atherosclerosis[27,30]. NO is now
recognised  to  play  a  critical  role  in  pathologic  processes  that  culminate  in  the
development of atherosclerotic lesions. Endothelial dysfunction is one of the earliest
processes identified in atherosclerosis development. The normal homeostatic function
of the endothelium requires NO, which has decreased bioavailability in patients with
developing atherosclerosis[28]. Deficiency in NO generation or functional availability is
a fundamental feature of atherosclerosis and many other processes associated with
cardiovascular disease, including thrombosis, intimal hyperplasia and aneurysm[28,29].
COMPLICATIONS FROM RADIAL ARTERY CANNULATION
Table 1 summarises the complications associated with radial artery cannulation.
Spasm
During RA cannulation, an early occurrence of RA spasm can result in difficulty to
advance  the  sheath  or  guide  catheter  within  the  artery,  or  failure  to  cannulate
altogether. RA spasm as a specific consequence of RA cannulation can occur at any
stage of the procedure. Spasm at the end of the procedure can result in difficult and
painful sheath removal. A report in 2004 indicated that severe spasm occurred in over
50% of patients that received transradial catheterization; incidence was inversely
correlated with arterial diameter[33].  However, most recent studies report a much
lower rate (1%-34%)[11,18,19,24,26,34-36], presumably due to improved technique. The large
range in reported RA spasm incidence (Table 1) is likely due to a combination of
factors, including sheath size, vessel size, procedural differences, experience of the
interventionalist, and the different definitions of spasm[24]. RA spasm is more common
in  females,  smaller  patients  and patients  with  vaso-occlusive  disorders  such  as
diabetes[22]. Spasm in the RA is generally temporary and resolves spontaneously, but
more prolonged spasm can occur, leading to trapping of the catheter and increased
risk of RA occlusion.
Other complications
It  is  out with the scope of this current review to discuss in detail  other potential
complications that can arise from RA cannulation, however their frequency is shown
in Table 1. In summary, reported rates of RA occlusion vary greatly from 1%-3% to up
to 19.7% (temporary occlusion)[11,19,24,26,35-37]. Perforation or rupture of the artery is a rare
complication that can lead to forearm haematoma[24]. More serious complications, such
as compartment syndrome, can occur[26,36].  Pseudoaneurysm is  an extremely rare
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Figure 1
Figure 1  Composition of the radial artery. The thick layer of tunica media contributes to the increased incidence of
radial artery spasm. Vessel sheath mismatch induces spasm and friction. Spasm promotes friction which in turn
induces more spasm, creating a continuous loop. The increased friction and spasm can lead to dissection of the
artery lining.
complication in the RA approach (more common in transfemoral procedures) and
occurs  when  an  artery  wall  is  injured,  resulting  in  possible  haemorrhage  and
haematoma in  the  surrounding tissue[11,26].  RA cannulation can also  cause  direct
damage to the endothelium, which can affect RA function[38,39] impairing endothelium-
dependent vasodilatory, anti-thrombotic and anti-mitogenic properties.
PREVENTING COMPLICATIONS
Administration of vasodilators, either alone or in an anti- spasmolytic cocktail is the
most  common  approach  to  the  prevention  or  management  of  spasm  (Table  2).
However, hydrophilic coatings and structural alterations of the sheaths are alternative
strategies that are available[32,37].
It is well recognised that RA spasm rates are lower in procedures conducted by
experienced operators with good technique and patient preparation is recognised to
be key to a successful procedure. Intraprocedural anticoagulation (usually heparin) is
routinely administered to prevent thrombotic occlusion of the RA; the occlusion rate
is inversely corelated to activated clotting time[15]. In selected cases, sedatives such as
short acting benzodiazepines can be used (or at least offered to patients) as a means of
reducing the incidence of spasm. Low dose sedation (opioid/benzodiazepine) has
been shown to reduce spasm (2.6% in treatment group vs 8.3% in control group)[40].
Vasodilators, such as NO donor drugs and calcium channel blockers can be used
alone, or in combination with other compounds, to form an anti-spasmolytic radial
“cocktail”, to prevent or reduce RA spasm[26,28,32,34]. However, on account of the risk of
systemic vasodilatory effects of spasmolytic drugs used in this setting, there are side-
effects associated with systemic hypotension and this approach is contra-indicated in
patients with pre-existing hypotension[15]. The use of a radial “cocktail” is based on the
operator’s preference but is common practise in many units[37].
Depending on the unit, the cocktail components and concentrations differ (Table 2),
along with  their  reported  effectiveness.  The  L-type  calcium channel  antagonist,
verapamil is reported to be the most widely used agent for preventing spasm[15,41].
Nitroglycerin [glyceryl trinitrate (GTN)] is also widely used in RA catheterisation.
GTN is metabolised to release NO in smooth muscle, resulting in smooth muscle
relaxation through activation of guanylate cyclase and increased cyclic guanosine
monophosphate.
A recent  review of  individual  drugs and drug cocktails  found that  the  use  of
verapamil (5 mg) alone or in combination with GTN (100-200 µg) was effective at
achieving a significant but modest reduction in the incidence of spasm (9% compared
to 12% for placebo)[41]. Despite these reported benefits of verapamil in this setting,
there is concern about the negative chronotropic and inotropic effect of verapamil,
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Table 1  Complications from radial artery puncture
Complication Frequency (%)
Radial artery spasm[11,18,19,24,26,34-36] 1-34
Radial artery occlusion[11,19,24,26,35-37] Up to 19.7
Haematoma[11,19,24,35] Up to 14.4
Dissection[35,36] Very rare (0.4)
Compartment Syndrome[26,36] Very rare
Pseudoaneurysm formation[11,19,26,35,36] Very rare up to 2.78
Infection[19,35] Up to 3.4
Perforation[26,36] Very rare
especially  in  those  patients  with  left  ventricular  dysfunction,  hypotension  and
bradycardia. It has been suggested that verapamil may not necessarily be required by
high-volume trans-radial-operators[42].  GTN is thought to have a more favourable
side-effect  profile  compared  to  verapamil  and  carries  the  additional  benefit  of
inhibiting platelet  aggregation.  However,  there  are  contraindications  of  GTN in
certain patients (e.g., severe aortic stenosis or severe hypotension[15,42]).
Development of a prophylactic vasodilator, with effects entirely localised to the
vasculature affected by spasm would be a distinct advantage.
Sheath type and materials
It has been suggested that the success rate of the RA approach is influenced by the
ratio of sheath diameter to vessel diameter. The anatomy of the RA varies between
patients, so vessel sheath mismatch is a potential issue[37]. In clinical practice, operator
experience and personal preference largely controls catheter selections[15]. Operators
will  generally  use  the  smallest  sheath  possible  and  therefore  there  is  limited
opportunity to further reduce sheath size. Several trials have evaluated the impact of
different sheaths and catheters on occurrence of RA spasm. Several investigations
have studied the impact of sheath length and coating, or the impact of sheath coating
alone.  In  a  study  conducted  by  Rathore  et  al[35],  the  application  of  4  different
introducer sheaths were examined: A long (23 cm) hydrophilic-coated, long uncoated,
short  (13  cm)  hydrophilic-coated,  and short  uncoated.  The  results  of  this  study
showed that the hydrophilic sheath coating caused significantly less RA spasm (19%
vs  39.9%)  and patient  discomfort  (15.1% vs  28.5%),  with  no  difference  observed
between long and short sheaths. Interestingly, RA occlusion was observed in 9.5% of
patients  but  this  was  unaffected by  sheath  coating  or  length.  One advantage  of
hydrophilic coatings is that larger sheaths can be used in smaller arteries[37]. Similar
results  have  been  found  in  other  studies,  but  despite  these  approaches  and
advancements, RA spasm continues to affect a sizable proportion of patients, even
with experienced operators.
Opportunity for a novel approach
The application of a novel sheath coating could be advantageous in the cardiovascular
setting, although the components of the coating would have to be carefully designed
to produce the desired effect without any adverse systemic effects. A sheath design
that dilates the vessel without the use of vasodilator drugs would not only minimise
the risk of RA spasm, but also reduce the risk of any unintended side-effects of the
drugs used. The application of NO to the sheath used in RA approach might provide
the local dilating effects of NO with the potential to avoid any unwanted systematic
effects.  It  would be essential that NO is delivered in appropriate quantities for a
suitable time scale, to prevent adverse effects and optimise vasodilation. The use of a
NO releasing coating of a sheath could prevent local vasospasm without prompting
systemic vasospasm, reducing patient pain and anxiety. The delivery of NO through
this  mechanism  could  also  inhibit  any  platelet  aggregation  prompted  by
catheterisation,  preventing thrombosis during the procedure.  Novel nanoporous
materials such as metal organic frameworks (MOFs) or zeolites are excellent gas
storage and release materials. Zeolites are inorganic, microporous materials often
used for large-scale catalytic applications[45,46]. MOFs are organic- inorganic crystalline
microporous materials made up of organic spacers which connect metal ions[47,48].
MOFs and zeolites have attracted interest for use in drug storage and delivery due to
the ability to tune their structure and function[45-48]. NO storage in both nanoporous
materials  has  been  studied  extensively  with  very  promising  results.  However,
cytotoxicity of these compounds is yet to be examined in the cardiac setting.
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Table 2  Variations of anti-spasmolytic cocktail components
Ref. Radial cocktailingredients Concentration Drug class
Kiemeneij et al[32] Verapamil 5 mg Calcium channel blocker1
Nitroglycerin 0.2 mg Nitrate2
Pancholy et al[44] Nitroglycerin 0.2 mg Nitrate2
Diltiazem 5 mg Calcium channel blocker1
Hizoh et al[43] Verapamil 5 mg Calcium channel blocker1
He et al[23] Heparin 2500 units Anticoagulant3
Nitroglycerin 0.2 mg Nitrate2
Verapamil 2.5 mg Calcium channel blocker1
Ruiz-Salmerón et al[24] Heparin with 5000 units Anticoagulant3
Verapamil or 2.5 mg Calcium channel blocker1
Phentolamine 2.5 mg Alpha-adrenergic antagonist1
1Disrupts the movement of calcium through calcium channels, causing vasodilation.
2Activates guanyl cyclase and increases cyclic guanosine monophosphate causing vasodilation;
3Inhibits coagulation, preventing thrombus formation.
Previous work examining NO-loaded zeolites showed evidence that these high
capacity NO stores could inhibit platelet aggregation over several hours. NO release
profiles could be easily tuned through manipulation of the metal ion, along with the
composition and nature of the polymer used for production. Stability studies also
found that NO-loaded zeolites were very stable in the absence of water, suggesting a
long shelf life of months to years under vacuum[46].  These data show promise for
potential use in a sheath coating. More recent developments in NO storage materials
have focused on the use of MOFs. MOFs have an advantage over zeolites due to the
infinite number of possible frameworks that can be synthesised. This ability to fine-
tune their structures provides an opportunity to alter chemical characteristics the suit
the required function. Many MOF structures have been developed to store and release
NO. Previous work has examined the capability of storage and release of NO in MOFs
with different incorporated metal ions. The alteration of metal ions allows for the
delivery of biologically active, but non-toxic levels of NO. It has been shown that the
use of Ni2+ as a dopant can improve the NO release performance of a MOF (CPO-27),
delivering an appropriate bio-active concentration of NO. The results from this study
highlights a significant advance in the development of a NO storage and delivery
compound[47]. A 2017 study examined the release of NO from vascular catheters to
prevent bacterial infection using a NO donor[49]. Results showed inhibition of bacterial
adhesion without any cytotoxic effects towards mammalian cells.  Another study
investigated the release of NO from a coronary stent using a NO donor[50]. Results
showed the promising positive effect of NO as a releasing agent to supress or prevent
restenosis and thrombosis. Authors proposed further investigations using other NO
carriers or donors to further improve NO release pattern.
The tuneable nature of these materials could allow for an appropriate release of NO
over  a  desired  period  thus  excluding  any  toxic  effects  that  may  occur  from
overexposure  of  NO.  The  effects  of  the  NO  released  should  ensure  a  larger
intraluminal diameter making the procedure safer and easier for the operator. The
localised nature of the NO release should inhibit inflammation and thrombosis at the
site  of  access  without  any  adverse  systemic  effects.  The  development  of  these
nanoporous materials has the potential for long-lasting, low level NO generation that
mimics endothelial NO, with the potential to both inhibit spasm and prevent localised
thrombosis. The use of a nanoporous material in the coating of a sheath could prevent
local vasospasm without prompting systemic vasospasm, reducing patient pain and
anxiety. Overall the procedure efficiency and effectiveness could be improved.
This application might not only benefit cardiac catheterisation, but other situations
where  catheter  thrombosis  or  platelet  aggregation  can  be  problematic  such  as
peripheral and central venous cannulae.
CONCLUSIONS
The use of the RA instead of the femoral artery has reduced complications at the time
of  coronary  artery  procedures.  However,  despite  improvement  in  cannulation
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techniques,  minimisation  of  sheath  size,  hydrophilic  coatings  and use  of  radial
“cocktails” complications still occur, most commonly RA spasm, in a proportion of
patients resulting is pain, procedural failure and RA damage. Novel approaches in
sheath  materials,  perhaps  to  include  NO releasing materials  such as  MOFs and
zeolites might offer an exciting new target for improvement in outcomes.
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